Active infection at the time of CD34+ selected stem cell boost is associated with treatment failure and poor overall survival.
Shapiro RM, Kim HT, Dulery R, Liney D, Garrity HM, Panaro K, Au C, Gervais C, Little JS, Ho VT, Cutler CS, Koreth J, Gooptu M, Antin JH, Kelkar AH, Romee R, Wu CJ, Ritz J, Soiffer RJ, Nikiforow S.
Shapiro RM, et al. Among authors: little js.
Blood Adv. 2024 Sep 10;8(17):4729-4737. doi: 10.1182/bloodadvances.2023012418.
Blood Adv. 2024.
PMID: 38748871
Free PMC article.